- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: BIIB059 is a fully humanized IgG1, clinical stage CLEC4C (BDCA2) targeting monoclonal antibody. It is being evaluated for ability to reduce release of disease-driving interferons (principally IFN-α) in SLE. BIIB059 was developed by Biogen, based on prior evidence of target engagement and SLE-applicable immunomodulatory efficacy of a humanized mAb against BDCA2 named 24F4A .
|BIIB059 is an investigational mAb targeting BDCA2, that is designed to disrupt type I IFN production by pDCs, as a disease-modifying mechanism to treat SLE.|
|Systemic lupus erythematosus||
|Clinical lead for SLE and CLE.|